ERBB2 and breast cancer: These ExVs stimulated responses of CD8+T cells capable of not only inducing killing activity in HER2+melanoma and trastuzumab-resistant BC cells in vitro, but also eradicating 6-day palpable HER2+BC [3–4 mm in diameter] in athymic nude mice.